RLAY zovegalisib progress targets breast cancer and vascular anomalies milestones
Updates cite robust progress in breast cancer and vascular anomalies programs, with zovegalisib showing strong efficacy and safety. Regulatory milestones and data readouts are expected by year-end, with a significant commercial opportunity for chronic therapy in rare disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.